Parkinsonian Phenotypes – towards New Nosology of Atypical Parkinsonian Syndromes


Authors: K. Farníková 1;  M. Bareš 2;  I. Nestrašil 3;  P. Kaňovský 1
Authors‘ workplace: Centrum pro diagnostiku a léčbu neurodegenerativních onemocnění, Neurologická klinika LF UP a FN Olomouc 1;  Centrum pro abnormní pohyby a parkinsonizmus, 1. neurologická klinika LF MU a FN u sv. Anny v Brně 2;  Department of Neurology, University of Minnesota, Minneapolis, USA 3
Published in: Cesk Slov Neurol N 2011; 74/107(6): 641-653
Category: Review Article

Overview

Parkinson’s disease is still viewed as a nosological entity (G20), yet it covers a wide range of clinical phenotypes characterised by the presence of parkinsonian syndrome with variable expression of a range of symptoms – motor, cognitive and behavioural – and an uncertain course. It appears that, largely thanks to progress in the recognition of phenotype variability and its clinico-pathological correlations at an ultrastructural level, it will divide into several close but separate nosological entities. In the last 50 years certain atypical parkinsonian syndromes have already split off one by one – Parkinson’s disease dementia (PDD), progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBGD), diffuse Lewy body disease (DLBD), frontotemporal dementia (FTLD) and the endemic parkinsonian syndromes such as Guam and Guadeloupean parkinsonism. However, the atypical parkinsonian syndromes are still diagnosed on the basis of (mainly obsolete) clinical dia­gnostic criteria which, at the time of their creation, only partially reflected the real pathological nature of the disorder. Their replacement with newly-developed criteria created on the basis of clinico-pathological correlation should be given priority in the field of translational research in the immediate future.

Key words:
Parkinson’s disease – atypical parkinsonian syndromes, clinico-pathological correlation


Sources

1. Parkinson J. An essay on the shaking palsy. London: Sherwood, Neely & Jones 1817.

2. Reichmann H. Clinical criteria for the diagnosis of Parkinson‘s disease. Neurodegener Dis 2010; 7(5): 284–290.

3. Marras C, Lang A. Invited article: changing concepts in Parkinson disease: moving beyond the decade of the brain. Neurology 2008; 70(21): 1996–2003.

4. Song YJ, Huang Y, Halliday GM. Clinical correlates of similar pathologies in parkinsonian syndromes. Mov Disord 2011; 26(3): 499–506.

5. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson‘s disease. Sicence 1997; 276: 2045–2047.

6. Shulman JM, DeJager PL, Feany MB. Parkinson‘s disease: genetics and pathogenesis. Annu Rev Pathol 2010; 6: 193–222.

7. Richardson JC, Steele J, Oslzewski J. Supranuclear ophtamoplegia, pseudobulbar palsy, nuchal dystonia and dementia. A clinical report on eight case sof „heterogenous system degeneration“. Trans Am Neurol Assoc 1963; 88: 25–29.

8. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333–359.

9. Williams DR, Holton JL, Strand K, Revesz T, Lees AJ. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord 2007; 22: 2235–2241.

10. Steele JC. PSP Steele-Richardson-Olszewski syndrome Richardson‘s disease. J Neurol Sci 2009; 285 (Suppl 1): S25.

11. Schwarz GA. The orthostatic hypotension syndrome of Shy-Drager. A clinicopathologic report. Arch Neurol 1967; 16: 123–139

12. Quinn N. Multiple system atrophy – the nature of the beast. J Neurol Neurosurg Psychiatry 1989; 52 (Suppl): 78–89.

13. Kaňovský P, Streitová H, Bareš M, Kuba R, Pospíšilová D. Multisystémová atrofie – nový nosologický koncept. Cesk Slov Neurol Neurochir 1996; 59: 3–9.

14. Stefanova N, Bücke P, Duerr S, Wenning GK. Multiple system atrophy: an update. Lancet Neurol 2009; 8(12): 1172–1178.

15. Fearnley JM, Lees AJ. Striatonigral degeneration. A clinicopathological study. Brain 1990; 113 (Pt 6): 1823–1842.

16. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson‘s disease. Mov Disord 2005; 20(10): 1255–1263.

17. Riedel O, Klotsche J, Spottke A, Deuschl G, Förstl H, Henn F et al. Cognitive impairment in 873 patients with idiopathic Parkinson‘s disease. Results from the German Study on Epidemiology of Parkinson‘s disease with Dementia (GEPAD). J Neurol 2008; 255(2): 255–264.

18. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 2010; 289(1–2): 18–22

19. Von Reichmann H, Deuschl G, Riedel O, Spottke A, Förstl H, Henn F et al. The German Study on the Epidemiology of Parkinson‘s Disease with Dementia (GEPAD): more than Parkinson. MMW Fortschr Med 2010; 152 (Suppl 1): 1–6.

20. Torres HA, Fratiglioni L, Hofman W, Winblad B. Early symptoms and neurological findings in demented subjects from a community survey. Alzheimer Dis Assoc Disord 1995; 9(3): 170–175.

21. Victoroff J, Mack WJ, Lyness SA, Chui HC. Multicenter clinicopathological correlation in dementia. Am J Psychiatry 1995; 152(10): 1476–1484.

22. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47(5): 1113–1124.

23. Mollenhauer B, Förstl H, Deuschl G, Storch A, Oertel W, Trenkwalder C. Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions. Dtsch Arztebl Int 2010; 107(39): 684–691.

24. Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain 1989; 112 (Pt 5): 1171–1192.

25. Rebeisz JJ, Kolodny EH, Richardson EP Jr. Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life. Trans Am Neurol Assoc 1967; 92: 23–26.

26. Lang AE. Parkinsonism in corticobasal degeneration. Adv Neurol 2000; 82: 83–89.

27. Litvan I, Grimes DA, Lang AE. Phenotypes and prognosis: clinicopathological studies of corticobasal degeneration. Adv Neurol 2000; 82: 183–196.

28. Doran M, du Plessis DG, Enevoldson TP, Fletcher NA, Ghadiali E, Larner AJ. Pathological heterogenity of clinically diagnosed corticobasal degeneration. J Neurol Sci 2003; 216(1): 127–134.

29. Wadia PM, Lang AE. The many faces of corticobasal degeneration. Parkinsonism Relat Disord 2007; 13 (Suppl 3): S336–S340.

30. Ling H, O‘Sullivan SS, Holton JL, Revesz T, Massey LA, Williams DR et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010; 133 (Pt 7): 2045–2057.

31. Strupp M. Corticobasal syndrome: a field of uncertainty. J Neurol 2011; 258(1): 173–175.

32. Berrios GE, Girling DM. Introduction: Pick‘s disease and the ‚frontal lobe‘ dementias. Hist Psychiatry 1994; 5 (20 Pt 4): 539–547.

33. Pick A, Girling DM, Berrios GE. On the symptomatology of left-sided temporal lobe atrophy. Classic Text No. 29. (Translated and annotated by D.M. Girling and G.E. Berrios.) Hist Psychiatry 1997; 8 (296 pt 1): 149–159.

34. Girling DM, Berrios GE. On the relationship between senile cerebral atrophy and aphasia. Hist Psychiatry 1994; 5: 542–547.

35. Schenk VW. Re-examination of a family with Pick‘s disease. Ann Hum Genet 1959; 23: 325–333.

36. Lynch T, Sano M, Marder KS, Bell KL, Foster NL, Defendini RF et al. Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology 1994; 44(10): 1878–1884.

37. Neary D, Snowden JS, Bowen DM, Sims NR, Mann DM, Yates PO et al. Cerebral biopsy in the investigation of presenile dementia due to cerebral atrophy. J Neurol Neurosurg Psychiatry 1986; 49(2): 157–162.

38. Miller BL, Cummings JL, Villanueva-Meyer J, Boone K, Mehringer CM, Lesser IM et al. Frontal lobe degeneration: Clinical, neuropsychological and SPECT characteristics. Neurology 1991; 41(9):1374–1382.

39. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994; 57: 416–418.

40. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51(6): 1546–1554.

41. Rohrer JD, Geser F, Zhou J, Gennatas ED, Sidhu M, Trojanowski JQ et al. TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology 2010; 75(24): 2204–2211.

42. Foster NL, Wilhelmsen K, Sima AA, Jones MZ, D‘Amato CJ, Gilman S. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann Neurol 1997; 41(6): 706–715.

43. Steele JC, McGeer PL. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology 2008; 70(21): 1984–1990.

44. Wszolek ZK, Vieregge P, Uitti RJ, Gasser T, Yasuhara O, McGeer P et al. German-Canadian family (family A) with parkinsonism, amyotrophy, and dementia – Longitudinal observations. Parkinsonism Relat Disord 1997; 3(3): 125–139.

45. Imamura A, Wszolek Z, Uitti R. Neurodegenerative overlap syndrome: parkinsonism and motor neuron disorder. Mov Disord 2007; 22(1): 151–152.

46. Farníková K, Kanovský P, Nestrasil I, Otruba P. Coexistence of parkinsonism, dementia and upper motor neuron syndrome in four Czech patients. J Neurol Sci 2010; 296(1–2): 47–54.

47. Uitti RJ, Berry K, Yasuhara O, Eisen A, Feldman H, McGeer PL et al. Neurodegenerative ‚overlap‘ syndrome: Clinical and pathological features of Parkinson‘s disease, motor neuron disease, and Alzheimer‘s disease. Parkinsonism Relat Disord 1995; 1(1): 21–34.

48. Caparros-Lefebvre D, Lees AJ. Atypical unclassifiable parkinsonism on Guadeloupe: an environmental toxic hypothesis. Mov Disord 2005; 20 (Suppl 12): S114–S118.

49. Lannuzel A, Ruberg M, Michel PP. Atypical parkinsonism in the Caribbean island of Guadeloupe: etiological role of the mitochondrial complex I inhibitor annonacin. Mov Disord 2008; 23(15): 2122–2128.

50. Anheim M, Lagier-Tourenne C, Stevanin G, Fleury M, Durr A, Namer IJ et al. SPG11 spastic paraplegia. A new cause of juvenile parkinsonism. J Neurol 2009; 256(1): 104–108.

51. Brait K, Fahn S, , Schwarz GA. Sporadic and familial parkinsonism and motor neuron disease. Neurology 1973; 23(9):990–1002.

52. Fallis BA, Hardiman O. Aggregation of neurodegenerative disease in ALS kindreds. Amyotroph Lateral Scler 2009; 10(2): 95–98.

53. Gilbert RM, Fahn S, Mitsumoto H, Rowland LP. Parkinsonism and motor neuron diseases: twenty-seven patients with diverse overlap syndromes. Mov Disord 2010; 25(12): 1868–1875.

54. Goizet CA, Boukhris A, Mundwiller E, Tallaksen C, Forlani S, Toutain A et al. Complicated forms of autosomal dominant hereditary spastic paraplegia are frequent in SPG10. Hum Mutat 2009; 30(2): E376–E385.

55. Hideyama T, Momose T, Shimizu J, Tsuji S, Kwak S. A positron emission tomography study on the role of nigral lesions in parkinsonism in patients with amyotrophic lateral sclerosis. Arch Neurol 2006; 63(12): 1719–1722.

56. Shintaku M, Oyanagi K, Kaneda D. Amyotrophic lateral sclerosis with dementia showing clinical parkinsonism and severe degeneration of the substantia nigra: report of an autopsy case. Neuropathology 2007; 27(3): 295–299.

57. Kato S, Oda M, Tanabe H. Diminution of dopaminergic neurons in the substantia nigra of sporadic amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 1993; 19(4): 300–304.

58. Bares M, Lungu O, Liu T, Waechter T, Gomez CM, Ashe J. Impaired predictive motor timing in patients with cerebellar disorders. Exp Brain Res 2007; 180(2): 355–365.

59. Bares M, Lungu OV, Husárová I, Gescheidt T. Predictive motor timing performance dissociates between early diseases of the cerebellum and Parkinson‘s disease. Cerebellum 2010; 9(1): 124–135.

60. Bareš M. Onemocnění mozečku. Neurol pro Prax 2007; 8(5): 267.

61. Bares M, Lungu OV, Liu T, Waechter T, Gomez CM, Ashe J. The neural substrate of predictive motor timing spinocerebellar ataxia. Cerebellum 2011; 10(2): 233–244.

62. Schöls L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 2004; 3(5): 291–304.

63. Maschke M, Oehlert G, Xie TD, Perlman S, Subramony SH, Kumar N et al. Clinical feature profile of spinocerebellar ataxia type 1-8 predicts genetically defined subtypes. Mov Disord 2005; 20(11): 1405–1412.

64. Manto MU. The wide spectrum of spinocerebellar ataxias (SCAs). Cerebellum 2005; 4(1): 2–6.

65. Fonteyn EM, Schmitz-Hübsch T, Verstappen CC, Baliko L, Bloem BR, Boesch S et al. Falls in spinocerebellar ataxias: Results of the EuroSCA Fall Study. Cerebellum 2010; 9(2): 232–239.

66. Freund HJ, Barnikol UB, Nolte D, Treuer H, Auburger G, Tass PA et al. Subthalamic-thalamic DBS in a case with spinocerebellar ataxia type 2 and severe tremor-A unusual clinical benefit. Mov Disord 2007; 22(5): 732–735.

67. Zumrová A, Mušová Z, Košťálová E, Apltová L, Křepelová A, Paděrová A. Autozomálně recesivní a X-vázané ataxie. Neurol pro Prax 2007; 8(5): 272–276.

68. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steel-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47(1): 1–9.

69. Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ et al. Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst 1998; 74(2–3): 189–192.

70. McKeith IG, Dickson DW, Lowe J, Emre M, O‘Brien JT, Feldman H et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005; 65(12): 1863–1872.

71. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y et al. Clinical diagnostic criteria for dementia associated with Parkinson‘s disease. Mov Disord 2007; 22(12): 1689–1707.

72. Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003; 54 (Suppl 5): S15–S19.

73. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 1998; 51(6): 1546–1554.

74. Přikrylová Vránová H, Mareš J, Nevrlý M, Stejskal D, Zapletalová J, Hluštík P et al. CSF markers of neurodegeneration in Parkinson‘s disease. J Neural Transm 2010; 117(10): 1177–1181.

75. Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 2006; 59(3): 449–458.

Labels
Paediatric neurology Neurosurgery Neurology

Article was published in

Czech and Slovak Neurology and Neurosurgery

Issue 6

2011 Issue 6

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account